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WEIGHT GAIN IN PREGNANCY AND PRE-MENOPAUSAL BREAST
CANCER: A POPULATION-BASED CASE-CONTROL STUDY
by
Arash Ardalan
Dr. Paulo Pinheiro, Examination Committee Chair
Assistant Professor of Epidemiology
University of Nevada, Las Vegas
ABSTRACT
Background: The risk of breast cancer increases transiently after pregnancy and then
falls to a lower level than for age-matched nulliparous women. Higher levels of estrogen
are known as the primary reason. Several pregnancy characteristics are thought to be
confounding the above link; however, except for the age at first pregnancy no other
pregnancy-related factor has been proved to be significant. Specifically, it has not been
established that an excessive weight gain in pregnancy is linked to the maternal risk of
breast cancer.
Objectives: To identify independent influence of weight gain in pregnancy on the risk of
pre-menopausal breast cancer following a delivery. We also examine the effect of
demographic factors and other relevant pregnancy characteristics on the risk of breast
cancer.
Methods: Our cohort consisted of 213,250 women who gave birth to a live neonate from
January 1, 1994 to December 31, 2003. We performed a nested population-based casecontrol study on 126 Nevada patients with a first lifetime breast cancer diagnosed from
January 1, 1995 through December 31, 2003, and 504 Nevada participants without breast
cancer. The two groups were matched on age at the recorded delivery. Our dataset was a
linkage between the Nevada Cancer Registry database for the years 1995–2008 and birth
certificates from the Nevada State Health Division for the years of 1994–2008.
Results: The excessive weight gain in none of the categories was associated with
increased risk of premenopausal breast cancer. After adjustment for other pregnancy
characteristics the results remained unchanged. Women whose pregnancies progressed
beyond 40 weeks of gestation were at significantly lower risk of developing breast cancer
up to five years following delivery, compared to the women who delivered at 37–40
weeks of gestation (OR 0.33, 95% CI 0.11–0.93), after adjustment for confounding
variables.
Conclusions: Our study did not show an association between excessive weight gain in
pregnancy and the risk of pre-menopausal breast cancer. However, pregnancies that
extended beyond 40 weeks of gestation were strongly associated with a lower likelihood
of pre-menopausal breast cancer up to 5 years after delivery. Biological plausibility for
this may relate to the fact that as pregnancy develops into more advanced stages,
mammary cells have more time to complete differentiation and maturation; a process that
started earlier in the third trimester. The results of this study will therefore contribute to
the literature and may provide a basis for future studies.
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CHAPTER 1: BACKGROUND
Breast cancer is the most common type of cancer among females and the second most
common cause of overall cancer death in the United States. It is also the main cause of
death in women between ages 40 to 59 worldwide.79 Risk factors for breast cancer
include age at menarche, age at first live birth, menopause, proliferative breast disease,
race, reproductive history, family history and genetic predisposition.76 The lifetime risk
of developing breast cancer is one in nine overall.23 The incidence of breast cancer
increased continuously by 3.7 percent per year starting in the 1980s in the U.S..43 That
trend is attributed to factors such as changes in reproductive patterns, long-term
menopausal hormone use, the rising prevalence of obesity, and increased detection
through screening mammography.63 The rates rose again from 1994 to 1999; however, it
declined from 1999 to 2007 by 1.8 percent per year.43 According to data from the Centers
for Disease Control and Prevention (CDC), 211,731 women were diagnosed with breast
cancer in 2009 in the U.S. and 40,676 of them died in the same year.89

Breast cancer is also the most frequently diagnosed cancer and the leading cause of
cancer death in female worldwide.37 Breast cancer is a disease of affluence and more
commonly seen in communities with high socioeconomic status.62 The incidence rates are
highest in North America, Australia, New Zealand, and in western and northern Europe,
and lowest in Asia and Sub-Saharan Africa.63,37 Although the rates decreased after 2000
in North America, breast cancer incidence continued to rise in other parts of the world,
such as Asia and Africa. These international differences are thought to be related to
industrialization factors such as changes in fat intake, body weight, age at menarche,
lactation, and reproductive patterns such as fewer pregnancies and later age at first
birth.66

Pregnancy-associated breast cancer is defined as breast cancer that occurs during
pregnancy or in the first year after delivery. The frequency of pregnancy-associated
breast cancer ranges from 1 in 3,000 to 1 in 10,000 deliveries.69 The risk of breast cancer
however remains high in the first few years after delivery and then falls to a lower level
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than for age-matched nulliparous women.44,15 A plausible explanation for the above
finding is that pregnancy increases the short term risk of breast cancer by stimulating the
growth of cells that had already commenced early stages of malignant transformation.
However, it provides long term protection by inducing the differentiation of normal
mammary stem cells that are prone to malignant change.53,72

Pregnancy associated breast cancer increases in rate as women delay childbearing until
later in life.2,15,44 In a case-control study of a nation-wide cohort in Sweden, nulliparous
women were found to be at a higher risk of breast cancer than age-matched multiparous
women up to 15 years after delivery and at a lower risk thereafter. The excess risk was
more prominent among women who were older at the time of their first pregnancy with
odds ratio (OR) 1.26 for 5 years after delivery among women 35 years old at first
delivery and 95% confidence interval (CI) 1.10–0.44. The study also showed that women
with two pregnancies had a lower risk of breast cancer later in life compared to mothers
of a single child.44 This is due to a long term protection provided by the first pregnancy.53

Although age at the first full-term pregnancy is known to be a strong predictor of
pregnancy-related breast cancer

2,4,44,46,88

other pregnancy characteristics and perinatal

factors may additionally play roles or affect the risk of breast cancer independently.
According to the results from a multi-center case-control study on 4,599 women of 20-55
years of age diagnosed with breast cancer as case subject and 4,536 controls, age at first
full-term pregnancy had a strong influence on the risk of breast cancer (OR 1.97 for
women older than 35 years compared to teen-aged women; 95% CI 1.30–2.97). After
controlling for other perinatal factors, the number of children and duration of
breastfeeding also significantly predicted the risk of breast cancer. Women of parity
seven or more had an adjusted relative risk of 0.59 (95% CI; 0.44–0.79) compared with
uniparous women for developing breast cancer, and there was a constant reduction in risk
as women continued to have more children. Women who had breastfed for 25 months or
longer had an adjusted relative risk of 0.67 (95% CI; 0.52–0.85), compared with parous
women who had never breastfed. The results did not support the prominent importance of
age at first full-term pregnancy among the reproductive determinants of breast
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carcinogenesis in a multivariate model (adjusted OR 1.58 for women older than 35
compared to teenaged mothers; 95% CI 1.032–2.42).46

The results from epidemiological studies have shown that the long-term protective effect
of pregnancy on breast cancer risk is preceded by a short-term adverse effect.4,15,44
According to a population-based prospective study of 802,457 Norwegian parous women
aged 20–56 years including 4,787 breast cancer cases, the risk of breast cancer was
lowest during pregnancy among all age groups and parities.4 Nonetheless, a short-term
post-delivery increase of the risk was also observed with a peak in 3–4 years after the last
birth, and the risk declined steadily thereafter. After the third or later pregnancies, the
maximum risk presented earlier (1–2 years after the last delivery). Women with three or
more children had lower risk than did nulliparous women in most categories of time since
the last birth. The above risk slightly increased among multiparous women with highest
risk after adjusting for only age at the time of delivery in all categories of time; however,
the peak remained the same. The authors concluded that a non-linear relationship existed
between breast cancer incidence and the time since the last birth.4

A study by Wohlfahrt et al. showed that following childbirth, breast cancer may occur in
a more advanced stage, together with higher rates of the disease.93 The risk of late-stage
breast cancer increases in the first few years of childbirth, and it tends to appear at a later
stage (a larger tumor, nodal involvement, or histologic grading II or III).94 According to a
population-based cohort study of 1.5 million Danish women, uniparous and bi-parous
mothers experienced a transient increased risk of late-stage breast cancer that did not
seem to be attributable to a delayed cancer diagnosis. The risk of having a tumor larger
than 5 cm in at least one dimension was 53% higher during the first 10 years after
childbirth compared with later in life.93 The high rate of late-stage breast cancer in the
first years after a birth might be attributed to delayed diagnosis or treatment of breast
cancer during pregnancy.60 This finding suggests that pregnancy-related factors can
transiently induce a high growth rate in cells that are already malignant and stimulate new
tumor growth.93
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The influence of pregnancy characteristics on early breast cancer was studied in a large
population-based case-control study of parous women aged 20–44 years, and the results
partially opposed the previous findings. The study found that women who reported
nausea or vomiting in their first pregnancy had a slightly lower risk of breast cancer
[relative risk (RR) 0.87; CI 0.72–1.0].88 This was attributed to relatively higher levels of
human chorionic gonadotropin (HCG) in pregnancy.51 Although the author found some
evidence for reductions in pregnancies with female twins (RR 0.48; 95% CI 0.20–1.3)
compared with singletons, the results did not reach a statistically significant level. Except
for age at delivery (RR 1.4 for women older than 30 at delivery compared to teenaged
mothers, CI 1–1.8) the study showed no associations for maternal risk related to
pregnancy characteristics.88 The authors support the idea that nulliparity is a risk factor
for breast cancer and each pregnancy adds small additional protection on this risk.40 A
full-term pregnancy earlier than age 30 particularly provides a strong protection against
breast cancer later in life. A plausible explanation for the observed difference is that
during pregnancy the levels of reproductive hormones mainly alpha-fetoprotein (AFP)
and HCG increase, and this can regress estrogen-dependent tumors.74

Although the hormonal effects of pregnancy on breast cancer are better known, it is still
possible that other changes during pregnancy predispose mothers to breast cancer
independently or through an effect on the estrogen levels. A plausible example of these
pregnancy characteristics could be pregnancy weight gain. During pregnancy, the breast
tissue undergoes proliferation in preparation for lactation. Estrogen stimulates normal
breast cells to differentiate to milk-secreting alveoli, while cells with malignant
degeneration may further develop into detectable tumors.20 Androgen is aromatized to
estrogen in adipose tissue67; thus a high body mass index is linked to elevated estrogen
levels. As a result, excessive weight gain during pregnancy can potentially cause higher
estrogen levels that may increase the risk of breast cancer later in life.75 According to a
case-control study within a cohort consisting of 2,089 Finnish women (123 cases of
breast cancer, and 856 controls), a weight gain of more than 15 kg during pregnancy was
associated with 62% higher risk of breast cancer (RR 1.62; 95% CI 1.03–2.53) compared
to women with the recommended weight gain of 11–15 kg after adjusting for mother's
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age at menarche, age at first birth, age at index pregnancy, parity at the index birth, and
BMI before the index pregnancy. Further investigations determined that the excessive
weight gain in pregnancy independently affected the risk of postmenopausal breast
cancer in their study; and case subjects did not transfer their pregnancy weight gain into
the postmenopausal period. Therefore, they did not have a higher BMI than the control
subjects at the time of breast cancer diagnosis (P value<0.05).42

The influence of pregnancy weight gain on premenopausal breast cancer was studied with
regards to BMI by Hilakivi-Clarck et al.28 however; the results were not consistent with
the previous findings. In a nested case-control study within a cohort of 22,610 Finnish
women, 114 cases of premenopausal breast cancer were identified. A total of 98 cases of
breast cancer and 392 controls were selected for the final model. According to the
analysis, women who gained 16 kg (35.2 Ibs) during their last pregnancy had a
significantly lower risk of breast cancer in the premenopausal period (OR 0.28; 95% CI
0.08–0.96) if their BMI increased >7 m/kg2 after the age of 20; however, the risk of
breast cancer increased later during post- menopause. The authors concluded that an
excessive pregnancy weight gain may provide short-term protection, but cause a longterm hazardous effect on breast cancer following menopause. It remained to be
determined why BMI and pregnancy weight gain affect premenopausal and
postmenopausal breast cancer risks differently.2
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CHAPTER 2: SPECIFIC AIMS
Although high levels of estrogen are known as cause of pregnancy-associated breast
cancer, it is still possible that other perinatal factors interfere with this relationship or
even cause breast cancer independently. The influence of different perinatal factors on
resultant breast cancer has been studied; however, except for the mother’s age at first
full-term pregnancy,2,4,44,46,88 other findings have not been consistent. A study by Luke et
al. showed a protective effect of excessive weight gain in pregnancy on the risk of breast
cancer in pre-menopausal women, although the risk rose later in postmenopausal life.28 In
this project, we aim to examine the independent effect of excessive weight gain in
pregnancy on the premenopausal risk of breast cancer. Up to our knowledge, there have
been only a couple of studies on this relationship that did not show consistent results.

The effect of weight gain during pregnancy on an early onset of breast cancer looks
plausible. A few mechanisms such as the hormonal effects of estrogen on pre-malignant
cells, increased testosterone aromatization in fat tissue, and increased cell proliferation
and gene mutation in pregnancy can explain the plausibility of our hypothesis.42,44
Although only a single study showed the above cause and effect relationship,42 and this
was not supported by other studies; it is still interesting to examine such a link in other
populations.

For the purpose of this study we will utilize two linked datasets: the Nevada Cancer
Registry (1995–2008), and the birth certificates of individuals born in Nevada (1994–
2008). The overall goals of this population-based case-control study are as follow:


To study whether changes occurring during pregnancy (mainly excessive weight
gain as predictive variable) can play a role in developing breast cancer (outcome
variable) in a period up to 5 years following delivery



To study whether other perinatal and prenatal factors such as birth weight, birth
order, gestational age, method of delivery and induction of labor, as well as
mother’s age at the time of delivery, race/ethnicity, level of education, plurality,
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smoking and drinking habits can potentially influence the risk of breast cancer in
a period of up to 5 years following delivery
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CHAPTER 3: RESEARCH QUESTIONS


Is an excessive weight gain during pregnancy associated with an increased risk of
breast cancer in a period of 5 years following delivery?



Can any variable of pregnancy or delivery such as birth weight, birth order,
gestational age, method of delivery and induction of labor, as well as mother’s
age at delivery, race/ethnicity, and level of education, plurality, smoking and
drinking habits, and marital status increase the risk of breast cancer during 5 years
following delivery?

The independent variable is excessive weight gain during pregnancy and the dependent
variable would be the new diagnosis of breast cancer during 5 years following delivery.
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CHAPTER 4: MAIN HYPOTHESIS
The null and the alternative hypotheses are as follows:

Ho: Excessive weight gain during pregnancy does not increase the risk of breast cancer
during 5 years following delivery.

Ha: Excessive weight gain during pregnancy is associated with an increased risk of
breast cancer during 5 years following delivery.
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CHAPTER 5: MATERIALS & METHODS
Data Source
Data for this population-based case-control study were obtained from two datasets: the
Nevada Cancer Registry with all cancer diagnoses in the state from January 1, 1995 to
December 31, 2008; and the birth certificates of individuals born from January 1, 1994 to
December 31, 2008 in the state of Nevada. Data from the two sources were linked based
on birth date; mother’s name and mailing address (all identifiable variables which were
not released with the working dataset) by the Nevada State Health Division. The data
include information about all cancer types occurring among the mothers as well as all
variables of pregnancy and delivery normally listed in a standard U.S. birth certificate.
The dataset also provides an enumeration of the population from which controls can be
sampled. Figure 2 illustrates the linkage between the two sources of data.

Figure 2. The linkage of the Nevada Cancer Registry database and the State of Nevada
birth certificates
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Participants
This is a population-based case control study. There is no interview or use of
questionnaires. The initial dataset (population pool) consisted of all women who gave
birth to a live baby from January 1, 1994 to December 31, 2008 in the state of Nevada.

The cases were defined as women who were diagnosed with premenopausal (<50 years
of age) breast cancer from January 1, 1995 to December 31, 2008 in the state of Nevada
after having delivered a live baby from January 1, 1994 to December 31, 2003 in the state
of Nevada. The control group included women who gave birth to a live baby during the
period of January 1, 1994 to December 31, 2003 and were not diagnosed with breast
cancer from January 1, 1995 to December 31, 2008 in the state of Nevada (Figure 1).

Women who were diagnosed with breast cancer following menopause (>50 years of age
was considered as cut-off point), women who were diagnosed with breast cancer prior to
the recorded delivery, and women with a diagnosis of cancer other than breast cancer
were excluded from the study (Figure 1).
Figure 1. The study population: inclusion and exclusion criteria
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Study Population
Initially, the study pool included all women who gave birth to a live baby from January 1,
1994, to December 1, 2008 in the state of Nevada. A cohort of 461,766 women between
the ages of 11 and 67 years whose delivery information was available through a birth
certificate was identified.

Research Design
We performed a nested case-control study within the abovementioned residents of
Nevada. Cases and controls were frequency-matched by the ratio of 1 to 4 by age of the
mother at delivery in categories of 5-year age groups.

According to some of the previous studies, breast cancer is most commonly diagnosed
within 3–4 years after a delivery,4 and so we limited cases and controls to a delivery date
of December 31, 2003; indicating the latest date of delivery providing enough time for
the individuals to develop breast cancer up to the last diagnosis year covered in the
dataset (2008).

The main predictor variable in our study was excessive weight gain during pregnancy,
and the outcome variable was the occurrence of breast cancer diagnosed in 5 years
following a full-term pregnancy, but prior to menopause. A weight gain of 36 Ibs or more
during a full-term pregnancy was considered as an excessive weight gain. We examined
the independent effect of 13 other covariates whose information is available in our
dataset, and the effect of the main variable was adjusted for these covariates in the final
model.

Selection of Cases and Controls
The initial dataset included 461,766 women who gave birth from Jan 1, 1994 to Dec 31,
2008 in the state of Nevada. The information about date of delivery (‘Date of Birth’) was
not available in the data and we were required to add the values of Last Menstrual Period
to that of the Gestational Week of mothers at the time of delivery in order to compute the
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delivery date. The data missed the information of at least one of the above variables for a
number of 83,735 women; therefore, these women were removed from the study.
A total of 213,250 mothers gave birth during the period of 1994─2003, of which 330
cases of breast cancer and 680 cases of other cancers were identified. The latter
population was excluded from the study. Among the remaining breast cancer cases, only
126 individuals were diagnosed with breast cancer up to 5 years after delivery, and those
were counted in the final model. The 126 cases of breast cancer did not include women
older than 50 years old; thus no one had to be excluded from the cases for this reason. We
selected four age matched controls for each case using frequency matching technique
(504 controls). Our final model consisted of 630 individuals (Figure 3).

Figure 3. The selection model for Cases and Controls
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Exposure Definition and Determination
Weight gain in pregnancy is defined as total extra weight that a mother gains during a
pregnancy, and that was already calculated by subtracting mother’s weight before
pregnancy from mother’s weight at delivery. The average weight gain in a normal
pregnancy is expected to be 25–35 pounds, which includes the baby (6–8 lbs), placenta
(1–2 lbs), uterus (1–2 lbs), amniotic fluid (2–3 lbs), breast (1–2 lbs), blood (3–4 lbs), and
body fluid (3–4 lbs).34

Weight gain in pregnancy depends on the Body Mass Index (BMI) before conception.
The guidelines for pregnancy weight gain are issued by the Institutes of Medicine (IOM).
According to the most recent recommendation, as of 2009, a woman with a normal BMI
(18.5–24.9) is expected to gain between 25 and 35 pounds during pregnancy. This is
equivalent to 1 to 5 pounds in the first trimester and an average of 1 pound per week for
the rest of the pregnancy for an optimal growth of the baby. Table 1 illustrates the normal
weight gain and the break, respectively, in a full-term pregnancy.30

According to the standard birth certificate issued by the Centers for Disease Control, the
subgroup recommended that mother’s pregnancy weight (Item 33) and mother’s weight
at delivery (Item 34) be added to replace the previous ‘weight gained during pregnancy’
item in an effort to gain more accurate information on the weight gained during
pregnancy. The height and the pre-pregnancy weight are needed in order to calculate
maternal BMI. As a matter of fact, maternal weight gain is of little value without the
knowledge of maternal BMI. Maternal BMI alone and in combination with maternal
weight gain during pregnancy is associated with the pregnancy outcome and maternal
morbidity and mortality.18

The weight gain during pregnancy can be measured using the Pregnancy Weight Gain
Calculator software which needs current information about mother’s weight and height,
and the gestational age of the fetus.33 For a twin pregnancy, the IOM recommends a
gestational weight gain of 16.8–24.5 kg (37–54 lbs) for women of normal weight, 14.1–
22.7 kg (31–50 lbs) for overweight women, and 11.3–19.1 kg (25–42 lbs) for obese
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women. There is no guideline available for estimating weight gain in a multiple gestation
pregnancy.33
There is also no clear definition for ‘excessive weight gain’ during pregnancy. A previous
study categorized total weight gain of more than 15 kg (33 Ibs) as more than normal
regardless of BMI and number of gestations.42However, by considering table 1 and for
the purpose of our study, we defined a weight gain of 35 Ibs or more as excessive weight
gain in pregnancy regardless of mother’s body mass index or number of fetuses, and we
classified it as mild (36–50 Ibs), moderate (51–65 Ibs), or severe (>65 Ibs) excessive
weight gain. Table 1 illustrates the Institute of Medicine’s weight gain guidelines for
pregnancy.78
Table 1. The Institutes of Medicine’s weight gain recommendations for pregnancy.

Ethical Considerations
Approval from the UNLV Institutional Review Board (IRB) was obtained. Our database
does not include names or patient identifications, and as a result the study was exempt
from IRB approval.
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CHAPTER 6: COVARIATES
Out of a total of 64 variables present in the database, we included only 13 covariates that
were believed to be relevant for the study through a plausible relationship with the
outcome variable. We studied the effect of each of these 13 predictor variables on the
outcome variable in both univariate and multivariate models.

The selected covariates included birth weight, birth order, gestational age and induction
of labor, as well as mother’s age at delivery, race/ethnicity, and levels of education,
plurality, smoking and drinking habits, gestational hypertension, and gestational diabetes.

Some of the covariates play the role of confounding factors in our study, and therefore we
computed and adjusted the influence of each of them on the risks of breast cancer in a
multivariate model. All variables were already measured and the results were available as
yes/no or a number (string and numeric) in our dataset. Table 2 shows the frequency of
each variable. Some of the covariates are defined below:
Age
Age is the second strongest risk factor for breast cancer following sex. Incidence rates
increase along with age steadily until about the age of 45 to 50, then the increase
continues but at a slower rate.38 Hormonal change due to menopause taking place at this
time may explain this pattern. The curve flattens at 75 to 80 years of age, and decreases
only mildly thereafter.14 According to data from 2002−2006, 95% of new cases and 97%
of deaths due to breast cancer occurred in women aged 40 and older; and the average age
at the time of diagnosis was 61 years.7

Pregnancy related breast cancer also increases in rate as women delay childbearing until
later in life; when the incidence of breast cancer would normally increase.2,38,44,46,88
However, it peaks at an earlier age than that of nulliparous women or women who gave
birth at younger ages.
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Race
According to the National Cancer Institute, white non-Hispanic women have the highest
overall incidence rate for breast cancer among U.S. ethnic groups, while Asian-American
women have the lowest rate (Fig. 4).8,38 Among women of ages 40─50, AfricanAmerican women have the highest incidence of breast cancer.35 Black women also have
the highest mortality rates from breast cancer in all age groups.16 Among women of all
races and ages, breast cancer mortality rates declined at an average rate of 2.3% per year
between 1990 and 2002, which reflects development in both early detection and
treatment.81

Figure 4. U.S. female breast cancer profile for 2002–2006: incidence and mortality rates
by age and race (American Cancer Society, Surveillance Research, 2009)

Birth Weight
Birth weight is the first weight of the baby measured right after being born. Birth weight
is measured on pounds scale, and a range of 5.5 to 10.5 Ibs is considered as normal birth
weight.36 A low birth weight of neonates (also known as ‘small for gestational age’) can
be due to prematurity or other reasons such as health issues of mother, genetic factors,
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problems with the placenta, and substance abuse by the mother.58 The term Fetal Growth
Restriction (FGR) (also called intrauterine growth restriction: IUGR) is used when a fetus
has not reached its expected growth; mainly due to genetic or environmental factors.

Small for gestational age (SGA) refers to a weight below the 10th percentile for
gestational age. Most of the fetuses who weigh below the 10th percentile for gestational
age are small only because of constitutional factors such as female sex or maternal
ethnicity, parity, or body mass index; and they are not at high risk of perinatal mortality
or morbidity.12 The incidence of FGR varies among populations, and increases with
decreasing gestational age. Approximately 23% of full-term infants in developing
countries are SGA; compared to only 10% of term infants in developed countries.10
High birth weight of neonates is often constitutional or due to maternal conditions during
pregnancy, mainly diabete.58 Infants are considered large for gestational age (LGA) if
their birth weight is greater than the 90th percentile for gestational age (equal to 3,800
grams).5

Factors related to intrauterine growth in the female offspring may increase adult risk of
breast cancer. A high birth weight is thought to be linked with risk of breast cancer later
in life.55,56,90 A high level of estrogen during embryonic life is thought to be the main
reason. Trichpopolos hypothesized this link in 1990; and it was subsequently supported
by a few studies; although some studies have been inconclusive or found no association.

Although the above link has been investigated by many studies and is generally
supported by the literature, there is little evidence that birth weight is associated with
maternal risk of breast cancer. To our knowledge, none of the case-control studies on the
association between pregnancy characteristics and maternal breast cancer have been able
to provide significant results on birth weight. This link has not been examined in an
observational study so far, or the results were inconclusive.
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Twin Pregnancy (Plurality)
Twin pregnancies have been increasing in proportion among total pregnancies in the
developed countries; which seems to be due to the expanded use of fertility treatments
and older maternal age at childbirth.8,71 In the United States, twin births accounted for
3.3% of live births in 2008.50 Multiple gestations are associated with higher rates of
almost every complication of pregnancy except for post-term pregnancy and fetal
macrosomia.19, 82

It has been hypothesized that the relatively higher estrogen levels in twin pregnancies
might be linked with higher risk of maternal breast cancer.21 However, support for this
seems to be insufficient, and in fact there are studies showing opposite results.27,39,
45,57,59,85,88

The higher levels of other pregnancy hormones such as progesterone and HCG

are suggested as a likely mechanism for association between multiple gestations and
reduced risk of maternal breast cancer.

Gestational Age
Gestational Age (GA) is defined as the length of the pregnancy, and is measured in weeks
by subtracting the date of the Last Menstrual Period (LMP) from the date of delivery
minus another 2 weeks.31 It is assumed that fertilization in humans normally occurs 14
days after the onset of the LMP.92 By agreement, only completed weeks of gestation are
counted. If a more precise gestational age is required, the number of remaining days is
added to the calculated complete weeks of gestation.52 A value of 37–40 weeks is
referred as normal GA for delivery or a normal full-term pregnancy. According to data
from CDC in 2005, the mean gestational age for singletons was 38.7 weeks.49

According to the World Health Organization, the American Academy of Pediatrics
(AAP) and the American College of Obstetricians and Gynecologists (ACOG), premature
birth is defined as the delivery of an infant prior to completion of 37 weeks of gestation.52
Infants born between 34 and 36 weeks of gestation are called as late preterm.22 Some
studies have defined late preterm birth as 35─36 weeks.32 Post-term pregnancy is defined
as a pregnancy that has extended beyond 42.0 weeks of gestation or 294 days from the
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first day of the last menstrual period.1 In 2005, around 6% of pregnancies continued
beyond 42 weeks of gestation.49 The prevalence of post-term pregnancy in a population is
influenced by several factors, but mainly by performing an early ultrasound assessment
of gestational age. The use of ultrasound for detection of gestational age early in
pregnancy has reduced the prevalence of post-term pregnancy to 2%.17,52

The incidence of premature births has increased from 10.6 percent in 1990 to 12.8
percent of all live births in 2006; and declined over three consecutive years to 12.2% of
all births in 2009.52 Changes in rates of late preterm birth (35th and 36th weeks of
gestation) is known to be the cause of this trend in 2006 and from 2007 to 2009.25

A preterm delivery was thought to be associated with increased risk of breast cancer. This
idea originated from a study that showed mammary cells proliferate in the first and
second trimester of pregnancy and differentiate in the last trimester among animals.73 It
was then hypothesized that a full term pregnancy is required for complete differentiation
of the mammary cells, and that early pregnancy termination or a pre-term labor may
elevate the risk of breast cancer. The assumption was examined a few times thereafter
and some evidence was found to support such link.29, 54,91 According to the results of a
study by Melbye et al., parous women who gave birth prior to 32nd week of gestation for
any reason had significantly higher risk of pre-menopausal breast cancer compared to
women who delivered at 40 weeks of pregnancy (RR 1.72; 95% 1.14−2.59). However, a
pre-term delivery after 32 weeks of gestation did not significantly change the risk of
breast cancer.54

Gestational Hypertension
Gestational hypertension or Pregnancy Induced Hypertension (PIH) is defined as systolic
blood pressure of ≥140 mmHg and/or diastolic blood pressure of ≥90 mmHg detected
after 20 weeks of gestation in a previously normotensive pregnant woman.70,77 The blood
pressure readings have to be documented on at least two occasions six hours apart.
Gestational hypertension is a temporary diagnosis for hypertensive pregnant women who
do not meet criteria for preeclampsia (both hypertension and proteinuria) or chronic
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hypertension (hypertension first detected before the 20th week of pregnancy). Gestational
hypertension occurs in about 6% of pregnancies.97

Preeclampsia is defined as hypertension after 20 weeks of gestation associated with
proteinuria (presence of protein> 3grams in a 24-hour urine sample), and is characterized
by dysfunction of the maternal endothelium.47 Given that many hormonal changes occur
with preeclampsia, it is possible that these changes influence the risk of maternal breast
cancer.41 According to a meta analysis of 13 relevant articles about preeclampsia and six
relevant publications about PIH, both preeclampsia84 (OR 0.86; 95% CI 0.73−1.01), and
PIH86 (OR 0.83; 95% CI 0.66−1.06) were found to have a protective effect on maternal
risk of breast cancer later in life.41

Gestational Diabetes
Women are normally prone to insulin resistance in pregnancy that predisposes them to
develop diabetes. The resistance is mainly caused by placental secretion of diabetogenic
hormones such as growth hormone, placental lactogenic hormone, and progesterone, as
well as an increased maternal adipose deposition, decreased exercise, and increased
caloric intake.46 Gestational diabetes is defined as having an abnormal glucose tolerance
test detected for the first time during the n pregnancy.68

According to the recent guideline issued by the American Diabetes Association in order
to diagnose a woman with gestational diabetes, she either has to have a fasting plasma
glucose ≥92 mg/dl and <126 mg/dl at any gestational age or to have an abnormal oral
glucose tolerance test (GTT). An abnormal GTT is defined as having a fasting plasma
glucose ≥92 mg/dL but <126 mg/dL or an one-hour blood sugar ≥180 mg/dL or a twohour blood sugar ≥153 mg/dL after a two-hour GTT with 75 grams of glucose.9

The prevalence rates of gestational diabetes are higher in African-American, HispanicAmerican, Native American, and Asian women than in white women in the United
States.11 Up to 16% of patients with breast cancer have type-1 or type-2 diabetes.
According to a meta-analysis of data on 43 studies, a significantly elevated risk of breast
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cancer was found to be associated with diabetes in women (OR 1.20; 95% CI 1.13−1.29).
The author concluded that diabetes independently increases the lifetime risk of breast
cancer in women.26 Gestational diabetes might also be associated with excess risk of
breast cancer.95
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CHAPTER 7: STATISTICAL ANALYSIS
The data were collected, cleaned, and recoded for use in this study. We compared the
demographic features and prevalence of major risk factors between case and control
subjects. We performed a case-control study of the association between excessive weight
gain during pregnancy and a breast cancer diagnosis. We measured the odds of excessive
weight gain during pregnancy in case patients in relation to breast cancer.

Regression analyses were conducted with the logistic procedure of SPSS 20. We utilized
unconditional logistic regression to determine the adjusted estimates of odds ratios and
respective 95% confidence intervals. Unadjusted odds ratios at 95% CI; as well as Pvalues for each variable were computed. The odds ratio for each one of the
abovementioned weight gain was adjusted for the potential confounding variables
described above. The background characteristics of the recorded pregnancies are shown
in table 2.
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Table 2. Background characteristics of the recorded pregnancies
Risk Factors
Age (years)
≤24
25–29
30–34
35–39
40–44
≥45
Race
White
Black
Hispanic
Native
Asian
Unknown
Education (years)
≤6
7–12
13–14
15–16
≥17
Unknown
Birth Weight (Ibs)
≤5.49
5.50–10.49
≥10.50
Unknown
Plurality
1
2
3
4

Cases
N=126 (%)

Controls
N=504 (%)

2 (1.5)
14 (11.2)
42 (33.3)
46 (36.6)
21 (16.6)
1 (0.7)

7 (1.3)
79 (15.6)
164 (32.5)
194 (38.4)
56 (11.1)
4 (0.7)

80 (63.8)
11 (8.7)
21 (16.6)
1 (0.7)
12 (9.5)
1 (0.7)

290 (57.7)
26 (5.1)
140 (27.7)
2 (0.3)
38 (7.5)
8 (1.5)

2 (1.5)
52 (41.2)
26 (20.6)
26 (20.6)
16 (12.6)
1 (0.7)

30 (5.9)
197 (39.4)
109 (21.6)
93 (18.4)
62 (12.3)
13 (2.5)

15 (11.9)
110 (87.3)
0
1 (0.7)

57 (11.3)
446 (88.4)
1 (0.7)
0

121 (97.0)
5 (2.3)
0
0

489 (96.0)
12 (3.9)
2 (0.3)
1 (0.1)

Risk Factors
Parity
1
2
Gestational Age (w)
≤34
35–36
37–40
≥41
Weight Gain
≤24
25–35
36–50
51–65
≥66
Alcohol
No
Yes
Unknown
Tobacco
No
Yes
Unknown
Induction of Labor
No
Yes
Hypertention
No
Yes
Diabetes
No
Yes
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Cases
N=126 (%)

Controls
N=504 (%)

125 (99.3)
1 (0.7)

499 (99.1)
5 (0.9)

4 (3.2)
10 (7.9)
108 (85.7)
4 (3.2)

21 (4.1)
28 (5.5)
406 (80.5)
49 (9.7)

26 (24.4)
47 (37.4)
34 (26.9)
8 (6.3)
11 (8.7)

123 (24.4)
185 (36.7)
124 (24.7)
21 (4.1)
51 (10.1)

121 (96.1)
3 (2.3)
2 (1.5)

487 (96.6)
12 (2.5)
5 (0.9)

107 (84.9)
18 (14.4)
1 (0.7)

437 (86.7)
62 (12.4)
5 (0.9)

94 (74.6)
32 (25.4)

368 (73.1)
136 (26.9)

121 (96.1)
5 (3.9)

490 (97.2)
14 (2.8)

124 (98.4)
2 (1.6)

497 (98.6)
7 (1.4)

CHAPTER 8: RESULTS
In the initial cohort, 330 women developed breast cancer from 1995 to 2008. A total of
126 cases aged 21─46 were eligible and entered the final model. The cases of breast
cancer had a mean age of 34.37 ± 4.57 at delivery and mean age of 37.88 ± 4.58 at the
time of diagnosis. The average time difference between the ages at the time of breast
cancer diagnosis and age at recorded delivery was 5.19 ± 1.46 years. The cases and
controls were matched on age at the time of delivery; thus we did not study the effect of
age on the risk of premenopausal breast cancer, although the values of every other
variable were adjusted for that. The unadjusted odds ratio of maternal breast cancer by
pregnancy characteristics is shown in Table3.

Table 3. Unadjusted odds ratio of maternal breast cancer by pregnancy characteristics
Risk Factors
OR
Race
White
Referent
Black
1.58
Hispanic
0.56
Native
2.02
Asian
1.14
Unknown
0.46
Education (years)
≤6
Referent
7–12
4.24
13–14
3.77
15–16
4.31
≥17
4.63
Unknown
1.11
Birth Weight (Ibs)
1–5.49 Ibs
1.11
5.5–10.49
Referent
Plurality
1
Referent
2
1.61
Parity
1
Referent
2
0.81
Gestational Age
(weeks)
17–34
0.63
35–36
1.33
37–40
Referent
41–48
0.32

95% CI P value

0.74–3.37
0.33–0.94
0.18–22.94
0.96–2.29
0.05–3.78

0.135
0.239
0.029
0.571
0.718
0.469

0.97–18.49
0.84–16.92
0.96–19.42
1.00–21.39
0.09–13.57

0.337
0.055
0.084
0.056
0.051
0.933

0.60–1.99

0.768
0.957

0.54–4.67

0.871
0.398

0.09–7.12

0.999
0.839

0.21–0.95
0.62–2.86
0.11–0.92

Risk Factors
Weight Gain (Ibs)
0–24
25–35
36–50
51–65
66+
Alcohol
No
Yes
Unknown
Tobacco
No
Yes
Unknown
Induction of Labor
No
Yes
Hypertention
No
Yes
Diabetes
No
Yes

0.446
0.464
0.122
0.034
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OR
1.17
Referent
1.32
1.88
0.99

95% CI P value
0.68–2.00
0.74–2.23
0.74–4.74
0.46–2.18

0.558
0.662
0.337
0.183
0.996

Referent
1.09 0.30–3.98
1.77 0.32–9.57

0.891
0.506
0.118

Referent
0.18 0.67–2.09
0.88 0.10–8.01

0.838
0.562
0.915

Referent
0.85 0.61–1.50

0.956

Referent
1.33 0.45–3.89

0.607

Referent
1.27 0.26–6.26

0.769

The average weight gain in pregnancy among cases was 38.34 ± 20.50 Ibs and for that of
controls was 37.33 ± 2.19 Ibs. An excessive weight gain was found among 42% of cases
and 39% of controls. Excessive weight gain was identified in 42% of patients with breast
cancer diagnosis and 39% of controls, giving odds ratio of 1.32, 1.87, and 0.99 for weight
gains of 36–50, 51–65, and +66 Ibs, respectively compared to the weight gain category of
25–35 Ibs as reference group. However, the values did not reach significant levels (Table
4).

A total of 17 mothers had twin pregnancies (5 cases and 12 controls). Two mothers had
triplet pregnancy and one had a quad pregnancy. Six mothers (1 case and 5 controls) had
their second pregnancy recorded in the dataset. Due to the low number of cases with
multiple gestational pregnancies as well as those with a second pregnancy, the results
were inconclusive on these variables.

Pregnancies that progressed beyond 40 weeks of gestation were associated with a
significant lower risk of premenopausal breast cancer compared to gestational week of
37−40 at the time of delivery (OR 0.32; CI 0.11─ 0.92). After adjustment for other
covariates in a multivariate model, the odds ratio remained significant (OR 0.32; CI
0.11─0.94). Preterm deliveries were not associated with changes in the risk of maternal
breast cancer.

The mean birth weight was 6.89 ± 1.38 Ibs for cases and 6.82 ± 1.57 Ibs for controls.
Among neonates, 556 were born in the normal range of birth weight, 72 were SGA, one
was LGA, and one neonate was with no value. The birth weight of the neonate did not
predict the maternal risk of premenopausal breast cancer in any category.

Whites made up the majority of the mothers in our study population (370), followed by
Hispanic (161), Asian (50), African-American (37), and Native American (3). Hispanic
background protected mothers against breast cancer compared to mothers of white
background (OR 0.56; 95% CI 0.33─0.94). Use of tobacco and alcohol, gestational
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diabetes, gestational hypertension, and induction of labor were not associated with
significant changes in the risk of premenopausal breast cancer.

Table 4. Distribution of risk factors and associated odds ratio for premenopausal breast
cancer among parous cases and controls after frequency-matching for the age of the
mother
Risk Factors
Race
White
Black
Hispanic
Native
Asian
Unknown
Education (years)
≤6
7-12
13-14
15-16
≥17
Unknown
Birth Weight (Ibs)
≤5.49
5.50-10.49
Plurality
1
2
Parity
1
2

OR

95% CI P Value

Referent
1. 75
0.61
1.92
1.13
0.62

0.80-3.80
0.35-1.11
0.17-22.47
0.55-2.32
0.06-6.08

0.282
0.161
0.114
0.626
0.739
0.687

Referent
2.58
2.34
2.62
2.65
0.76

0.55-12.01
0.48-11.49
0.53-12.98
0.52-13.66
0.05-11.07

0.755
0.229
0.294
0.239
0.244
0.833

0.98
Referent

0.43-2.20

Risk Factors
Gestational Age
(weeks)
≤34
35-36
37-40
≥41
Weight Gain (Ibs)
≤24
25-35
36-50
51-65
≥66
Alcohol
No
Yes
Tobacco
No
Yes
Induction of Labor
No
Yes
Hypertention
No
Yes
Diabetes
No
Yes

0.998
0.951

Referent
1.52

0.39-5.93

0.947
0.456

Referent
0.48

0.03-6.99

0.595
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OR

95% CI P Value

0.77
1.3
Referent
0.33

0.19-3.09
0.53-3.19

1.07
Referent
1.21
2.03
1.03

0.61-1.86

0.11-0.93

0.714
0.564
0.171
0.038

0.66-2.20
0.74-5.20
0.44-2.41

0.815
0.707
0.941
0.167
0.953

Referent
0.81

0.20-3.20

0.766
0.999

Referent
1

0.53-1.90

0.999
0.985

Referent
0.92

0.58-1.48

0.743

Referent
1.5

0.46−4.88

0.497

Referent
1.62

0.30−8.68

0.575

CHAPTER 9: DISCUSSION
A relatively higher level of estrogen during pregnancy associated with early stages of
malignant transformation is known as a likely cause of the elevated rates of breast
cancer.72 Mammary cells in a few percent of women might be in early stages of
malignant transformation at the time of pregnancy and raising estrogen to higher levels
enhances the growth of cells in an already malignant region. This theory is consistent
with the fact that the risk of breast cancer increases as women delay the age of their first
pregnancy.2,4,44,46,88 In fact, the chances of showing early stages of malignancy or being in
higher stages of malignant transformation increases with the pregnancy occurring at
relatively older ages. The theory of higher levels of estrogen during a delayed first-time
pregnancy as a possible mechanism to increase the risk of a subsequent breast cancer65
seems to lack sufficient scientific basis, this is because the ovaries start regressing in size
and function as the woman ages.

It is also possible that there are other pregnancy-related factors confounding this
relationship, producing relatively higher levels of estrogen in some pregnant women, or
even causing breast cancer independently. Examples of such confounding factors may
include an excessive weight gain in pregnancy and preterm delivery.42,54 A few other
pregnancy-related factors such as breastfeeding,46 female twins,88 and preeclampsia41
have also been suggested to have protective effects against premenopausal breast cancer
among mothers, although not consistently.

It is not clear whether the number of parities is associated with the risk of premenopausal
breast cancer. While some studies showed that the rates decrease following a second,
third or a subsequent pregnancy4,44,46 other studies were not consistent with this finding
or even showed opposite results.88 The mechanism of this protection if it even exists is
not well understood. The long term protective effect of first pregnancy through the
introduction of mature mammary cells is known as a likely mechanism of risk reduction
of breast cancer later in life.53
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Our study did not support a likely role of weight gain during pregnancy on the risk of
premenopausal breast cancer. Although there is little evidence for such link drawn from a
single study by Kinnunen et al..42 To our knowledge, the only significant results on the
above link should be due to the protective effects of weight gain during pregnancy on the
premenopausal risk of breast cancer,28 in which the postmenopausal increased risk of
breast cancer is only partially explained by the known mechanisms of hormonal
stimulation of pregnancy on the premalignant proliferation of mammary cells.

Although the information about BMI at delivery was not available in our dataset and a
couple of previous studies controlled for it, this should not alter our definition of
excessive weight gain during pregnancy; and we are not concerned whether the mothers
normally gained weight during pregnancy. With regard to the theory of conversion of
testosterone to estrogen in fat tissue,80 the total weight gain in pregnancy was targeted as
a likely predictor of breast cancer rather than the value of the basal BMI. Although
higher baseline estrogen levels might correlate with higher BMI, we are mainly looking
for the differences in estrogen levels due to changes during pregnancy. It is also not
feasible, perhaps even in a prospective study, to monitor the levels of estrogen hormone
through pregnancy due to the diurnal variation in its levels.83,96

Our study had a high level of strength and validity. The fact that it was a nested casecontrol study within a cohort of Nevada residents enabled us to minimize the risk of
selection bias (the whole population is included) or recall bias (the data contained
measurable variables which were already measured and listed in our dataset; there are no
subjective characteristics of pregnancy listed in our dataset). In addition, the design of the
study allowed us to examine the aforementioned link over a population from all
socioeconomic classes. We were also able to examine a large number of variables as
likely causes of breast cancer following a pregnancy.

Our study, like many other previous studies, had a number of limitations. The linking of
the two sources of data (Cancer Registry database and birth certificates) based on name,
date of birth, and residential information but no social security number could be a source
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of incomplete matching or misclassification. In fact, it is possible that a portion of the
control subjects actually had breast cancer and their information is not recorded in the
dataset. It is also possible that some patients left the state of Nevada following a
pregnancy and developed breast cancer elsewhere. We are not able to clarify whether the
individuals who are counted as control subjects developed breast cancer while they
moved and lived in a different state. However, the probability of this is negligible given
the low incidence of premenopausal breast cancer in the population at large.

In our analysis, we were not able to control the study for some of the confounding factors
such as BMI at baseline, age at menarche, history of breast feeding, using mammography
as a screening tool, family history of breast cancer, and genetic predispositions (e.g.,
BRCA 1 and BRCA 2 genes) due to unavailability of the information. Breastfeeding is
shown to protect women against breast cancer.46,61 The effects of genetic factors and
familial predispositions are also already known and the use of mammography has caused
higher and earlier rates of detecting breast cancer cases.24 A long duration of exposure to
estrogen due to early menarche or late menopause or both is known to be a risk factor for
breast cancer.13

The most interesting finding of our study was the effect of gestational age at the time of
delivery on the risk of maternal breast cancer, which is plausible.54,75 The theory of
proliferation of mammary cells in the first and second trimester and cell differentiation
and maturation in the third trimester73 explains the positive influence of pre-term delivery
on the risk of premenopausal breast cancer among mothers.54 This theory also applies for
the protective effects of late deliveries on premenopausal risk of breast cancer. We
suggest that as pregnancy progresses beyond 40 weeks of gestation, mammary cells have
more time for complete differentiation and maturation; a process that started earlier in the
third trimester. To our knowledge, this link was not previously shown. The results of this
study will therefore contribute to the literature and may provide a basis for future studies.
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CHAPTER 10: CONCLUSIONS
Our study did not find a role of excessive weight gain on the risk of premenopausal breast
cancer. There is little to no evidence that weight gain in pregnancy is associated with
maternal risk of breast cancer. This link can potentially be examined in a different
population, a larger number of participants, or a different study design controlling for
BMI at baseline. The association of pregnancy progressing beyond 40 weeks of gestation
and reduced risk of maternal breast cancer is significant and plausible. This link needs to
be studied further in a cohort study with different populations.

The impact of such a finding on public health could be significant. Delivery through
elective cesarean section or induction of labor has been increasingly performed for the
past couple of decades. The procedures are both normally preferred after the completion
of a minimum of 38 weeks of pregnancy.64,86 In order to minimize the premenopausal
risk of breast cancer for women with known risk factors, it may be beneficial to schedule
a relatively later gestational age for the aforementioned procedures — beyond 40 weeks
of gestation if the delivery does not progress naturally before then.
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protocol. You will be notified via email and/or campus mail after the protocol has been
reviewed.
ORI – HS can be reached at IRB@unlv.edu or call 702-895-2
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